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Abstract 17 
Objective: The natural history of type II endoleaks and linkage to aneurysm rupture is unclear. 18 
Likewise, treatment recommendations are controversial. The aim of this study was to 19 
examine the incidence, factors associated with type II endoleaks and outcomes in an Australia 20 
cohort of patients who have undergone endovascular AAA repair (EVAR). 21 
Methods: Data from 693 patients who underwent EVAR between 2009 and 2013 at multiple 22 
institutions across Australia were studied. Patients who developed a) type II endoleak and b) 23 
type II endoleak with sac expansion, were compared for preoperative demographics, 24 
mortality, sac expansion, aneurysm rupture and intervention rates.   25 
Results: A total of 225 patients developed type II endoleak over a mean follow-up of 1.9 years 26 
(±1.0 years), out of which 133 spontaneously resolved, 37 were untreated unresolved and 16 27 
underwent intervention. Type I and III endoleaks occurred in 50 and 19 patients respectively. 28 
Smoking (p=0.002) and Warfarin (p=0.044) were protective factors for development of type 29 
II endoleak whilst age (p=0.034), right iliac artery tortuosity (p=0.031), and right (p=0.008) and 30 
left external iliac diameters (p=0.028) were risk factors for endoleak. Three patients suffered 31 
aneurysm ruptures in the entire cohort. All ruptures occurred in type II endoleak patients, of 32 
which two occurred after reintervention and in the absence of sac expansion (>5mm). Late 33 
type II endoleak occurred in 117 patients, out of which 26 had sac expansion. Of those without 34 
late type II endoleak, 25 has sac expansion. There was no statistically significant difference in 35 
survival between those with and without type II endoleak. Age (p<0.0001) and smoking 36 
(p=0.001) were significant independent predictive factors for survival in this patient sample. 37 
Treatment outcomes were encouraging with most cases involving endoleak resolution (15 of 38 
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16 patients) and no sac expansion post intervention (0 of 8 patients with complete follow-up 39 
info on sac size).  40 
Conclusion: Aneurysm rupture in patients with type II endoleak is uncommon in our series. 41 
Type II endoleak with sac expansion does not appear to be associated with aneurysm rupture. 42 
In this series, most aneurysm ruptures occurred in the absence of documented sac expansion 43 
and after reintervention.  44 
 45 
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1. Introduction 48 
Type II endoleak (T2EL) is the commonest complication of endovascular aneurysm repair (EVAR) and 49 
due to an insufficient understanding of its role in aneurysm sac rupture, optimum treatment 50 
recommendations are presently uncertain.  51 
The risk of sac expansion in patients with type II endoleak is unclear1. Sac expansion of 5mm has been 52 
reported to be associated with aneurysm rupture2, but according to a more recent review by Sidloff 53 
et al, in over one third of patients with type II endoleak who suffer aneurysm ruptures, this occurs in 54 
the absence of documented sac expansion1. This suggests that there may be other unidentified factors 55 
involved in the mechanism of aneurysm rupture in type II endoleak and highlights the concern of using 56 
sac expansion as a surrogate marker for risk of aneurysm rupture in management of type II endoleak.   57 
Treatment outcomes for type II endoleak are also suboptimal, with recurrence of type II endoleak 58 
found in a third of patients following transarterial embolizations and around one fifth following 59 
translumbar embolizations. A large proportion of patients are found to have persistent sac expansion 60 
despite either treatment of type II endoleak.1.  61 
The current guidelines of the European Society of Vascular Surgery recommend a conservative 62 
approach to managing type II endoleak which involves reintervention with increased sac diameter ≥10 63 
mm, with conversion to open surgery if endovascular treatment fails (level 2b)3.  There are studies 64 
however, that recommend more aggressive approaches to treatment, such as intervening at ≥5mm4, 65 
or in cases of persistent or recurrent type II endoleak regardless of sac expansion5, 6 . 66 
It is therefore important to clarify the natural history of type II endoleak and treatment outcomes, 67 
which will guide the establishment of more appropriate treatment guidelines.  68 
The key objectives of this present study are to evaluate the incidence, outcomes, predictive factors 69 
and treatment success of type II endoleak in patients who have undergone EVAR for infrarenal AAA in 70 
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Australia with particular reference to rates of sac expansion, death, interventions, aneurysm rupture 71 
and treatment success. This will assist with the development of better treatment recommendations.  72 
  73 
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2. Materials and Methods 74 
 75 
Data were collected prospectively between 2009 and 2013 in this multicenter study from 67 surgeons 76 
at 29 institutions throughout Australia. Institutions included both public tertiary centers and private 77 
hospitals. A total of 693 patients who underwent EVAR for infrarenal AAAs were entered onto a 78 
prospective database which was analysed retrospectively. Collected data included perioperative 79 
demographics and follow-up information such as aneurysm size, detection of type II endoleak, deaths, 80 
aneurysm ruptures, and treatments performed.  The follow-up period was 3 years, with follow-up 81 
intervals of 1, 6, 12, 24 and 36 months. Ultrasound (USS) and Computed Tomographic Angiography 82 
(CTA) imaging were used during follow-up. Ethical clearance was obtained from the Queen Elizabeth 83 
Hospital Ethics of Human Research Committee, the Australian Institute of Health and Welfare and 84 
from all institutions contributing data to the EVAR trial.  85 
Incidence of type II endoleak was defined by the presence of a type II endoleak at any point in the 86 
study, and included type II endoleaks combined with other endoleaks, e.g. type I and III endoleaks. 87 
Patients with combined type II endoleaks (two types of endoleaks) were included in the analysis of 88 
type II endoleak outcomes. The detection of type II endoleak is based on CTA and USS evidence, and 89 
the clinical judgment of the surgeon. Type II endoleak was further classified into early (demonstrated 90 
within 30 days) and late type II endoleak (type II endoleak occurring after 30 days). Sac expansion was 91 
defined as ≥5mm increase in aneurysm diameter. Anything less was regarded as stable sac size. All 92 
Australian death data were obtained from the Australian Institute of Health and Welfare National 93 
Death Index. Mortality was recorded in terms of overall, 30-day and twelve-month mortality rates. 94 
Survival analysis included variables with <10% incomplete data and involved two approaches. One 95 
approach was to assess the effects of Type II endoleak on survival reported as an unadjusted model 96 
along with a model adjusted for confounding factors. The other approach was to develop a model that 97 
contained significant, independent predictors of survival. 98 
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Preoperative Computed Tomographic Angiography (CTA) scans were prospectively reviewed for 99 
several anatomic variables which included aneurysm diameter, infrarenal neck length and diameter, 100 
infrarenal neck shape, aortic and aneurysm angles, diameters of iliac arteries, prevalence of aortic 101 
neck thrombus (as judged by the treating surgeon on the preoperative CTA),, presence of saccular 102 
aneurysm, occlusive aorto-iliac disease, arteries involved in the aneurysm sac, patency of Inferior 103 
Mesenteric Artery (IMA) and iliac tortuosity. Iliac tortuosity was defined as the extent of tortuosity of 104 
the common iliac arteries as assessed by the clinician using the following categories: none (i.e. 105 
straight), mild, moderate or severe. This scoring is subjective. 106 
2.1 Statistical analysis 107 
Statistical analyses were performed using SAS Version 9.3 (SAS Institute Inc., Cary, NC, USA) -. The data 108 
were summarized as means with standard deviations or percentages as appropriate. Group 109 
comparisons were made using Pearson’s Chi-squared test or Fisher’s exact test for categorical 110 
variables and Wilcoxon (Mann Whitney) test for continuous variables. The association between any 111 
Type II Endoleak and survival was summarized as median survival and assessed using a Cox 112 
Proportional Hazards model. Independent predictors of survival were identified using regression 113 
modelling. All tests were two-tailed and significance was assessed at p<0.05. 114 
3. Results 115 
3.1 Incidence of type II endoleak and preoperative variables 116 
Out of 693 patients in Australia who underwent EVAR, 225 patients developed a type II endoleak. 117 
Median follow-up was 1356 days (95% CI: 1303-1404 days) for the type II endoleak group and 1466 118 
days (95% CI: 1288-1576 days) for the no type II endoleak group (p=0.760). Combined type II endoleaks 119 
occurred in 9 patients, with 6 patients having combined type I and II endoleaks and the other 3 having 120 
combined type II and III endoleaks. Type I and type III endoleaks occurred in 50 and 19 patients 121 
respectively. The majority of the grafts were Zenith (Cook) grafts (67%) and the aorto-bi-iliac-bifurcated 122 
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configuration was used in over 90% of cases. The prevalence of type II endoleaks was higher in patients 123 
treated with the Excluder (Gore) device (54.2%) when compared to Zenith (Cook) (32.2%) and 124 
Endurant (Medtronic) (26.0%) devices (P=0.001). While the Excluder device was used in only 8% of 125 
patients, it accounted for 14% of type II endoleaks. 126 
During the procedure, 124 type II endoleaks were detected. At first postoperative imaging and on 127 
discharge, 71 cases of type II endoleak were detected. At 36 months, 26 type II endoleaks were 128 
detected. The number of patients with type II endoleak detected both perioperatively and at some 129 
point during follow-up reduced from 23 at discharge to 7 at 36 months.  130 
In terms of preoperative variables, smoking (p=0.002) and Warfarin therapy (p=0.044) were shown to 131 
be associated with a significantly lower risk of type II endoleak. Age (p=0.034), right iliac tortuosity 132 
(p=0.031), right (p=0.008) and left external iliac diameter (p=0.028) were shown to significantly 133 
increase the risk of type II endoleak (Table I).  134 
3.2 Aneurysm ruptures, mortality and survival 135 
A total of three patients in the entire cohort suffered aneurysm rupture in the present study. All of 136 
them had type II endoleak reported during the study, of which one had a type I endoleak documented 137 
perioperatively. In this patient, the type I endoleak resolved after re-stenting the right limb within the 138 
original graft perioperatively, but a type II endoleak was subsequently detected at 1-month follow-up, 139 
then at 6 and 12 months until reintervention with Onyx glue at 24 months. Despite post-intervention 140 
endoleak resolution and absence of documented sac expansion during follow-up, rupture occurred at 141 
36 months resulting in death. The two other patients with ruptures had isolated type II endoleaks. Of 142 
these patients, one had a type II endoleak documented at 1 and 6 months before undergoing 143 
reintervention at 12 months with coiling. Despite post-intervention endoleak resolution and absence 144 
of documented sac expansion during follow-up, rupture also occurred at 36 months. The other patient 145 
with isolated type II endoleak, did not undergo reintervention. In this patient, type II endoleak was 146 
detected perioperatively, but not at 1, 6 and 12 months. At 24 months, type II endoleak was detected 147 
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again with rupture occurring at 36 months. There was a documented sac expansion of 14mm in the 2 148 
years leading up to the rupture. In summary, of the three patients with ruptures, all had type II 149 
endoleak, and two had ruptures in the absence of sac expansion (>5mm), and two had ruptures 150 
despite successful endoleak resolution post-reintervention.  151 
A total of 104 (mean follow-up in this cohort was 1.9 years) deaths were recorded over the course of 152 
the present study. Of these, 28 deaths were amongst type II endoleak patients and 76 were amongst 153 
patients without type II endoleak. Median survival was 1356 days amongst patients who had had a 154 
Type II endoleak. This compares to 1466 days amongst those who had not had a Type II endoleak. 155 
While the hazards of dying were somewhat lower amongst patients who had had a Type II endoleak, 156 
the difference between the two patient groups was not significant (HR = 0.80; 95% CI: 0.51-1.24; 157 
p=0.313) (Figure 1). 158 
There was no statistically significant difference in survival between those with and without type II 159 
endoleaks (Table II and III). However, older age and active smoking were found to be significant, 160 
independent predictors of decreased survival in this patient sample (Table IV). 161 
3.3 Sac expansion 162 
Sac expansion was reported in 35 patients with a type II endoleak. An overall sac expansion (> 5 mm) 163 
was recorded in 24 patients, of whom, 5 died and 4 underwent an intervention. Of the 5 deaths in 164 
patients with sac expansion, 4 deaths were non-aneurysm related and 1 was of unknown cause. 17 165 
deaths were reported amongst type II endoleak patients without sac expansion, while 20 patients 166 
required intervention.  167 
None of the perioperative variables were found to be significantly associated with T2EL and sac 168 
expansion (Table V).  169 
Late type II endoleaks were reported in 117 patients (excluding the perioperative type II endoleaks). 170 
Of the 117 patients with late type II endoleak, 26 had sac expansion and 91 did not have sac expansion. 171 
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Of the 26 patients with sac expansion, 5 died and 10 underwent intervention. Of the 91 patients 172 
without sac expansion, 19 died and 15 underwent intervention. Sac expansion was reported in 25 173 
patients who did not have a late type II endoleak; of these, 8 died and 3 underwent intervention. 62 174 
deaths were reported in patients without sac expansion and a further 33 of these patients underwent 175 
intervention (Table VI).  176 
3.4 Outcomes of treatment of type II endoleaks 177 
Out of 225 patients with type II endoleak, 186 patients had adequate follow-up information regarding 178 
treatment or resolution outcomes. Of these, 133 had spontaneous resolution, 37 had an unresolved 179 
type II endoleak but were being observed untreated, 28 underwent a diagnostic or other procedure 180 
to fix a complication but 16 underwent reintervention specifically for the type II endoleak, and thus 181 
form the treatment group. 182 
Of the 16 patients treated for type II endoleak, at the time of the procedure, endoleak resolution 183 
occurred in 15 patients. For the one patient without endoleak resolution, intervention was indicated 184 
for a persistent type II endoleak with sac expansion of 17mm. The intervention involved embolization 185 
at 3 years which was close to the end of the follow-up period. This gave little time for observing 186 
endoleak resolution and assessing post-intervention reduction in sac size. 187 
Indications for intervention in the present study included persistent type 2 endoleak (endoleak for 188 
longer than 6 months) in 8 patients, persistent type II endoleak with sac expansion in 5 patients, and 189 
sac expansion alone in 3 patients. All sac expansions in these patients were >5mm, except for one 190 
patient with 2mm sac expansion (5-5.2cm) with abdominal pain. Three patients had sac expansion 191 
exceeding 10mm prior to intervention. For the patients with sac expansion alone as their indication 192 
for treatment, type II endoleak was present at the time of documented sac expansion. No resolution 193 
of endoleak occurred prior to the onset of documented sac expansion or prior to intervention. 194 
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Following endoleak treatment, death occurred in 3 patients, with 2 being non-aneurysm related. The 195 
one patient with aneurysm-related death, died of a ruptured aneurysm at 3 years, described under 196 
‘Aneurysm ruptures, mortality and survival.’ Only 8 patients with treated type II endoleaks had 197 
sufficient follow-up information regarding sac size, out of which none had sac expansion (6 had sac 198 
shrinkage and 2 had stable sac sizes). These 8 patients had undergone a range of interventions, 199 
including 1 with laparoscopic ligation of inferior mesenteric artery, 3 with coiling, 2 with embolization 200 
with embolic agent unspecified, 1 with open repair, and 1 with a bifurcated graft placed into the old 201 
tube graft. Indications for intervention in these 8 patients included 5 for persistent type II endoleak, 1 202 
for persistent type II endoleak with sac expansion >5mm, and 2 for sac expansion alone, one being 203 
>5mm and the other >10mm.  204 
4 Discussion 205 
Our study demonstrates that not all aneurysm ruptures occur in the setting of sac expansion. Other 206 
unknown factors are involved. Although aneurysm rupture is uncommon in type II endoleak, the 207 
occurrence of rupture has been shown to be unpredictable. This explains the uncertainty in knowing 208 
when to intervene to prevent such a fatal outcome. Despite the unclear treatment indications, the 209 
present study shows that treatment outcomes are encouraging 210 
The number of perioperative type II endoleaks of the present study appears much higher than that of 211 
the earlier Australian ASERNIP study. The current study identified 124 type II endoleaks out of 693 212 
patients compared with 69 out of 959 patients respectively7. This could be due to improved procedural 213 
imaging.  214 
Our study found a significantly lower incidence of type II endoleak with smoking (p=0.002) and 215 
anticoagulation with warfarin (p=0.044). Smoking has been reported as a protective factor for type II 216 
endoleak in other studies5, 8-10, including the study by Koole et al.11. Accelerated atherosclerosis from 217 
smoking might narrow or occlude the inferior mesenteric and lumbar arteries. Warfarin has not been 218 
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reported a protective factor in other studies. Studies specifically looking at Warfarin and its association 219 
with type II endoleak have either reported it to be a risk factor12 or as insignificant8, 13, 14. Older age 220 
(p=0.034) was found to be a significant risk factor for type II endoleak in the present study, which is 221 
supported by several studies5, 8-10. Nonetheless, there are also several studies which report it to be 222 
insignificant6, 13-16.  223 
Other significant anatomical variables such as right iliac tortuosity, right and left external iliac 224 
diameters have not been evaluated by other studies to date.  The extent of right iliac tortuosity in the 225 
present study is a subjective measure based on its determination by clinician assessment using the 226 
four categories of severity. In our study, the graft type used was relatively homogenous, and therefore 227 
a comparison of endoleak incidence with each graft type is unlikely to be meaningful. Pre-emptive 228 
coiling of the inferior mesenteric artery was performed in only one patient, and they did not develop 229 
any endoleak over the three years. 230 
All three aneurysm ruptures in the present study occurred in patients with type II endoleak. This may 231 
suggest that aneurysm ruptures are more likely to occur in type II endoleak. Sac expansion is 232 
commonly used as a surrogate marker for risk of aneurysm rupture1, and sac expansion of 5mm has 233 
been previously reported as a risk factor for rupture2. The European Society of Vascular Surgery 234 
guidelines recommend intervention at 10mm sac expansion3. As all ruptures occurred in patients 235 
without documented sac expansion, it may be that sac expansion per se is not a surrogate for sac 236 
pressurization. Alternatively, sac re-expansion may have occurred between the time of last follow-up 237 
and presentation with rupture. Causes for aneurysm rupture other than sac expansion have not been 238 
clearly identified to date. More studies are needed to determine other factors in type II endoleak that 239 
could lead to rupture.  240 
There was no statistically significant difference in survival between those with and without type II 241 
endoleaks Age and smoking were found to be significantly associated with decreased survival in this 242 
patient sample. Age has already been reported as a factor associated with poorer long-term (5-year) 243 
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survival in patients following EVAR in other studies17, 18. Smoking has not been reported as a predictive 244 
factor for survival following EVAR to date. A review paper by Lottman et al, has found that mortality 245 
does not significantly differ between smokers and non-smokers after EVAR19. A systematic review by 246 
Khashram et al, however, reports that patients with Chronic Obstructive Pulmonary Disease (COPD) 247 
requiring supplemental oxygen is associated with poor long-term survival following abdominal aortic 248 
aneurysm repair, i.e. either open or endovascular20. COPD mostly occurs in chronic smokers. Perhaps 249 
the impact of smoking on survival after EVAR becomes move evident when smoking occurs for long 250 
enough to impair respiratory function.  251 
Treatment outcomes seemed satisfactory, given that most type II endoleaks resolved and had sac 252 
shrinkage rate post intervention. Both currently used techniques (translumbar vs transarterial), 253 
embolic agents (glue, onyx, coils), and ligation (open, laparoscopic) used seemed to obtain 254 
satisfactory results. Limitations to this study include variations in criteria used for treating the type II 255 
endoleaks, as the data came from multiple institutions with EVARs performed by different surgeons. 256 
Another limitation is that only 186 out of 225 patients with type 2 endoleak had adequate follow-up 257 
information due to some patients being lost to follow-up, some surgeons failing to supply follow-up 258 
data, and some patients being non-compliant with follow-up. A recent published study examined 259 
rates of compliance to post-EVAR surveillance and showed only 43% of patients were compliant21, 260 
which is a similar result to that of our study. 261 
5 Conclusion 262 
In summary, the present study suggests that type II endoleak with sac expansion does not appear to 263 
be associated with aneurysm rupture. Treatment outcomes were encouraging. Aneurysm ruptures in 264 
type II endoleak are uncommon but occurred in the absence of documented sac expansion raising the 265 
need to identify factors other than sac expansion that can cause aneurysm rupture in type II endoleak.  266 
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Tables 330 
Table I: Baseline characteristics of patients with and without Type II endoleak 331 
Preoperative variables* Type II endoleak  
= 225 (32.4%)† 
No Type II endoleak 
 = 468 (67.5%) 
p-value 
Aneurysm diameter, mm 
(mean, ±sd) 
58.55 (±10.22)‡ 58.09 (±9.46) 0.995 
Infrarenal neck length, mm 
(mean, ±sd) 
27.67 (±12.46) 29.08 (±13.80) 0.390 
Infrarenal neck diameter, 
mm (mean, ±sd) 
23.27 (±3.03) 23.85 (±3.59) 0.106 
Aortic neck angle, degrees 
(mean, ±sd) 
20.04 (±18.90) 16.84 (±16.48) 0.078 
Thrombus in neck (number, 
%) 
39 (25.83)§ 98 (32.45) 0.148 
Occlusive aorto-iliac disease 
(number, %) 
11 (7.19) 50 (15.38) 0.435 
Saccular aneurysm (number, 
%) 
22 (14.10) 16 (5.35) 0.712 
Artery involved in aneurysm 
sac (number, %) 
122 (77.71) 242 (72.89) 0.254 
Aneurysm angle, degrees 
(mean, ±sd) 
27.53 (22.05) 25.48 (21.79) 0.308 
RCIA diameter, mm (mean, 
±sd) 
15.64 (5.86) 15.58 (6.06) 0.890 
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LCIA diameter, mm (mean, 
±sd) 
14.71 (4.20) 14.73 (4.71) 0.874 
REIA diameter, mm (mean, 
±sd) 
9.48 (1.52) 11.43 (44.50) 0.008 
LEIA diameter, mm (mean, 
±sd) 
9.43 (1.65) 9.24 (2.94) 0.028 
RCIA tortuosity (number, %) 
   
None 34 (22.22) 94 (28.75) 
0.031 
Mild 90 (58.82) 145 (44.34) 
Moderate 23 (15.03) 71 (21.71) 
Severe 6 (3.92) 17 (5.20) 
Patency IMA (number, % 
patent) 
86 (60.14) 172 (58.11) 0.055 
Age, years (mean, ±sd) 75.21 (±7.77) 74.02 (±7.73) 0.034 
Gender (number, %) 
   
Male 200 (88.89) 421 (90.00) 
0.847 
Female 24 (10.67) 48 (10.26) 
Medications (number, %) 
   
Warfarin  15 (6.73) 53 (11.73) 0.044 
Statin  154 (68.75) 315 (68.78) 0.941 
Beta-blocker 82 (36.94) 165 (36.11) 0.800 
Smoking (number, %) 
   
Current 29 (13.30) 108 (24.00) 
0.002 Ex-smoker 141 (64.68) 274 (60.89) 
Never 48 (22.02) 68 (15.11) 
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*For each categorical variable, the number and proportion of patients with that variable out 332 
of all patients with and without type II endoleak (who had sufficient data for that variable) 333 
are recorded. LCIA tortuosity, RCIA and LCIA calcification, ASA, BMI, CIA isolated, and 334 
infrarenal neck shape were also all insignificant. ASA: American Society of Anesthesiologists 335 
grading; BMI: Body Mass Index, CIA: common iliac artery; RCIA: Right common iliac artery; 336 
LCIA: Left common iliac artery; REIA Right external iliac artery; LEIA: Left external iliac artery; 337 
IMA: Inferior mesenteric artery; sd: standard deviation 338 
†Number, % of patients with and without type II endoleak are reported in the header row.  339 
‡Continuous data are shown as the mean ± standard deviation (sd) 340 
§Categorical data are shown as number and %.  341 
  342 
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Table II: Univariate associations: survival analysis 343 
Parameter Label HR* Lower CL Upper CL P 





















Beta blocker  Beta blocker (yes) 
















































 1.01 0.99 1.04 0.1669 
RCIA diameter  0.99 0.95 1.03 0.7188 
LCIA diameter  1.01 0.97 1.06 0.5070 
REIA diameter  0.96 0.85 1.08 0.4789 
LEIA diameter  0.96 0.86 1.08 0.5398 
*HR: hazards ratio; CL = confidence level; ASA: American Society of Anesthesiologists grading; 344 
BMI: Body Mass Index; CIA: common iliac artery; RCIA: Right common iliac artery; LCIA: Left 345 
common iliac artery; REIA Right external iliac artery; LEIA: Left external iliac artery;  346 
  347 
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Table III: Adjusted and unadjusted models for association between Type II endoleak and survival 348 
 Unadjusted Adjusted* 























*Adjusted for age, sex, and smoking status 350 
†HR: hazards ratio; CL = confidence level 351 
  352 
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Table IV: Independent predictors of survival  353 

















1.17 – 4.66 








*HR: hazards ratio; CL = confidence level 355 
  356 
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Table V: Baseline characteristics in type II endoleak patients with vs without sac expansion 357 
Preoperative variables* Type II endoleak 
with sac expansion 
at any time= 35 
(23.3%)† 
Type II endoleak 
without sac 
expansion at any 
time = 115 (76.7%) 
p-
value 
Aneurysm diameter, mm (mean, ±sd)  57.16 (±9.60)‡ 58.82 (±10.35) 0.416 
Infrarenal neck length, mm (mean, 
±sd) 
28.10 (±13.27) 27.60 (±12.38) 0.447 
Infrarenal neck diameter, mm (mean, 
±sd) 
23.75 (±2.39) 23.17 (±3.14) 0.326 
Aortic neck angle, degrees (mean, 
±sd)  
18.87 (±20.39) 20.25 (±18.71) 0.426 
Thrombus in neck (number, %) 4 (20.00)§ 35 (26.72) 0.523 
Occlusive aorto-iliac disease 
(number, %) 
2 (9.09) 9 (6.87) 0.660 
Saccular aneurysm (number, %) 3 (13.04)  19 (14.29) 1.000 
Artery involved in aneurysm sac 
(number, %) 
18 (78.26) 104 (77.61) 0.945 
Aneurysm angle, degrees (mean, ±sd) 27.96 (±19.81) 27.45 (±22.48) 0.727 
RCIA diameter, mm (mean, ±sd) 15.28 (±6.16) 15.71 (±5.81) 0.557 
LCIA diameter, mm (mean, ±sd) 15.09 (±6.67) 14.64 (±3.54) 0.206 
REIA diameter, mm (mean, ±sd) 9.45 (±1.51) 9.48 (±1.53) 0.718 
LEIA diameter, mm (mean, ±sd) 9.51 (±1.52) 9.42 (±1.67) 0.860 
Age, years (mean, ±sd) 
 
76.09 (±6.48) 75.04 (±7.99) 0.845 
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RCIA tortuosity (number, %) - - 
 
None  9 (39.13)  25 (19.23) 
0.200 
Mild 12 (52.17) 78 (60.00) 
Moderate 2 (8.70) 21 (16.15) 
Severe 0 (0.00) 6 (4.62) 
Patency IMA (number, % patent) 11 (50.0) 75 (61.98) 0.167 
Gender (number, %)   
 
Male  31 (88.5) 169 (89.42) 
0.774 
Female 4 (11.43) 20 (10.58) 
Medications (number, %)    
Warfarin  3 (8.82) 12 (6.38) 0.708 
Statin  24 (68.57) 130 (69.15) 0.946 
Beta-blocker 13 (37.14) 69 (37.10) 0.996 
Smoking (number, %)   
 
Current 3 (8.57) 26 (14.21) 
0.617 Ex-smoker 23 (65.71) 118 (64.480 
Never 9 (25.71) 39 (21.31) 
*For each categorical variable, the number and proportion of patients with that variable out 358 
of all patients with and without type II endoleak (who had sufficient data for that variable) are 359 
recorded. LCIA, ASA, BMI, CIA isolated, and infrarenal neck shape were all insignificant. ASA: 360 
American Society of Anesthesiologists grading; BMI: Body Mass Index; CIA: common iliac 361 
artery; RCIA: Right common iliac artery; LCIA: Left common iliac artery; REIA Right external iliac 362 
artery; LEIA: Left external iliac artery; IMA: Inferior mesenteric artery; sd: standard deviation 363 
†Number, % of patients with and without type II endoleak are reported in the header row.  364 
‡Continuous data are shown as the mean ± standard deviation (sd)  365 
§Categorical data are shown as number and %.  366 
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Table VI: Influence of sac expansion on death and intervention in patients with late type II 368 
endoleak 369 
 All Sac expansion >5mm† No Sac expansion >5mm 
 Total Mortality Intervention Total Mortality Intervention Total Mortality Intervention 
Late type 2 
endoleaks* 
117‡ 24 25 26 5 10 91 19 15 
No late type 
2 endoleaks 
458 70 36 25 8 3 433 62 33 
 370 
*Late type 2 endoleaks: type 2 endoleaks detected after 30 days 371 
†’Sac expansion >5mm’ refers to patients with sac expansion of greater than 5mm at any point 372 
following EVAR 373 
‡Data on sac expansion, mortality, intervention are all reported as number of patients in the table 374 
*Note: this table above is required to be printed in color 375 
  376 
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Figure 1: Kaplan-Meier survival curve comparing survival between patients with type II endoleak 377 
















*Note: this figure above is required to be printed in color 394 
 395 
Median survival amongst patients who had and had not had a Type II endoleak 
 







No 1466.00 1289.00 1576.00 
Yes 1356.00 1167.00 1404.00 
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